ALK and lung cancer: Several phase I and II studies are currently studying the potential benefit and tolerability of the combination between ALK TKI and immune checkpoint inhibitors in lung cancer, such as ceritinib with nivolumab, alectinib with cobimetinib, lorlatinib with crizotinib and binimetinib, ceritinib with trametinib, alectinib with cobimetinib, and brigatinib with binimetinib and the results are highly awaited [47,143].